M W Kattan1, M E Cowen, B J Miles. 1. Matsunaga-Conte Prostate Cancer Research Center, Baylor College of Medicine, Houston, TX 77030, USA.
Abstract
OBJECTIVE: To determine the preferred treatment of clinically localized prostate cancer. DESIGN: Cancer grade, patient age, and comorbidities are considered in a Markov model with Monte Carlo sensitivity analyses. Large and recent pooled analyses and patient-derived utilities are included. RESULTS: Principal findings suggest benefit for radical prostatectomy relative to watchful waiting for men under 70 years of age with low to moderate comorbidity. Men older than 70 with high comorbidity and disease of low to moderate grade do better with watchful waiting. CONCLUSIONS: Cohort-level sensitivity analyses suggest a quality-based treatment benefit for radical prostatectomy for younger men and treatment harm for older men. Tailored patient and clinician decisions remain necessary, especially for men older than 70 in good health but with aggressive cancers.
OBJECTIVE: To determine the preferred treatment of clinically localized prostate cancer. DESIGN: Cancer grade, patient age, and comorbidities are considered in a Markov model with Monte Carlo sensitivity analyses. Large and recent pooled analyses and patient-derived utilities are included. RESULTS: Principal findings suggest benefit for radical prostatectomy relative to watchful waiting for men under 70 years of age with low to moderate comorbidity. Men older than 70 with high comorbidity and disease of low to moderate grade do better with watchful waiting. CONCLUSIONS: Cohort-level sensitivity analyses suggest a quality-based treatment benefit for radical prostatectomy for younger men and treatment harm for older men. Tailored patient and clinician decisions remain necessary, especially for men older than 70 in good health but with aggressive cancers.
Authors: G S Gerber; R A Thisted; P T Scardino; H G Frohmuller; F H Schroeder; D F Paulson; A W Middleton; D B Rukstalis; J A Smith; P F Schellhammer; M Ohori; G W Chodak Journal: JAMA Date: 1996-08-28 Impact factor: 56.272
Authors: D G Fryback; E J Dasbach; R Klein; B E Klein; N Dorn; K Peterson; P A Martin Journal: Med Decis Making Date: 1993 Apr-Jun Impact factor: 2.583
Authors: Giovanni Lughezzani; Alberto Briganti; Pierre I Karakiewicz; Michael W Kattan; Francesco Montorsi; Shahrokh F Shariat; Andrew J Vickers Journal: Eur Urol Date: 2010-08-06 Impact factor: 20.096
Authors: Çağatay Doğan; Hamza M Gültekin; Sarper M Erdoğan; Hamdi Özkara; Zübeyr Talat; Ahmet N Erözenci; Can Öbek Journal: Am J Mens Health Date: 2016-09-21
Authors: Claudio Jeldres; Nazareno Suardi; Paul Perrotte; Umberto Capitanio; Jochen Walz; Georg C Hutterer; Fred Saad; Luc Valiquette; Markus Graefen; Hugues Widmer; Pierre I Karakiewicz Journal: Can Urol Assoc J Date: 2009-02 Impact factor: 1.862
Authors: Jennifer Ku; Murray Krahn; John Trachtenberg; Michael Nesbitt; Robin Kalnin; Gina Lockwood; Shabbir M H Alibhai Journal: Can Urol Assoc J Date: 2009-12 Impact factor: 1.862
Authors: Alex Z Fu; Kristi D Graves; Roxanne E Jensen; John L Marshall; Margaret Formoso; Arnold L Potosky Journal: J Cancer Res Clin Oncol Date: 2015-11-18 Impact factor: 4.553
Authors: Arthur S Elstein; Gretchen B Chapman; Joan S Chmiel; Sara J Knight; Cheeling Chan; Robert B Nadler; Timothy M Kuzel; Amy K Siston; Charles L Bennett Journal: Health Expect Date: 2004-06 Impact factor: 3.377